The Patent Paradox: Unmasking the Abusive Art of Evergreening
Keywords:
Ever greening, pharmaceutical companies, intellectual property rights, public health, abuse of patent systemAbstract
Evergreening refers to a controversial practice in the pharmaceutical industry where companies extend the lifespan of their patents by making minor modifications to existing drugs in order to obtain new patents. This abuse of the patent system has been a subject of intense debate and criticism, as it can hinder innovation, limit competition, and increase healthcare costs. This research paper examines the concept of evergreening and its implications for the pharmaceutical industry, particularly in the context of intellectual property rights and public health. The paper explores the different strategies used by pharmaceutical companies to evergreen their patents, such as making slight changes to the chemical structure, formulation, or dosage of an existing drug, or seeking additional patents for new uses or methods of administration. Furthermore, the paper discusses the consequences of evergreening on healthcare systems, patients, and society at large. It highlights how evergreening can delay the entry of generic medicines into the market, leading to higher prices and reduced affordability of essential medications. The paper also discusses the ethical implications of evergreening in the context of global health, particularly in low-income countries where access to affordable medicines is critical for public health outcomes. This research paper sheds light on the practice of evergreening as an abuse of the patent system in the pharmaceutical industry. It highlights the various strategies employed by
pharmaceutical companies to extend their patent monopolies and the legal, ethical, and societal implications of such practices. The paper calls for greater scrutiny and regulation of evergreening to promote innovation, competition, and access to affordable medicines for the benefit of public health.
References
Kumar, R., Srivastava, S. and Kumar, S. (2017) Intellectual Property Rights: Principles and Procedures. Meerut: Rama Publishing House.
D.R.S. et al. (2020) Ever greening patents - a welcome move or hidden enemy, iPleaders. Available at: https://blog.ipleaders.in/evergreening-patents-welcome-move-hidden-enemy/ (Accessed: April 13, 2023).
D.R.S. et al. (2020) Ever greening patents - a welcome move or hidden enemy, iPleaders. Available at: https://blog.ipleaders.in/evergreening-patents-welcome-move-hidden-enemy/ (Accessed: April 13, 2023).
Atkinson, J.D.M. and Moodie, R.S. (2013) “Legitimate patent extension or patent system abuse?” Pharmaceutical Patent Analyst, 2(3), pp. 317–324. Available at: https://doi.org/10.4155/ppa.13.24.
Mehta, S.K. “Ever greening of patents,” in Intro to IPR. 1st edn. Delhi: Law legal Agency, pp. 55–58.
Mehta, S.K. “Ever greening of patents,” in Intro to IPR. 1st edn. Delhi: Law legal Agency, pp. 60.
“The Indian Supreme Court weighs in on ‘patent evergreening’” (2013) Forefront Group [Preprint]. Available at: https://doi.org/10.1377/forefront.20130403.029809.
“The Indian Supreme Court weighs in on ‘patent evergreening’” (2013) Forefront Group [Preprint]. Available at: https://doi.org/10.1377/forefront.20130403.029809.
Gamharter, K. (2004) “Access to affordable medicines and the TRIPS Agreement,” Access to Affordable Medicines, pp. 3–108.
Hassoun, N. (2020) “Global health impact.” Available at: https://doi.org/10.1093/oso/978019 7514993.001.0001.
Baxi SM, Beall RF, Yang JS, Mackey TK. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. 2019 Sep 18 [cited 2023 May 16];15(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751842/
Hazel Moir Adjunct Associate Professor; economics of patents and Deborah Gleeson Lecturer in Public Health (2023) Explainer: Evergreening and how Big Pharma Keeps Drug Prices High, The Conversation. Available at: https://theconversation.com/explainer-evergreening-and-how-big-pharma-keeps-drug-prices-high-33623 (Accessed: April 12, 2023).
“Novelty—the invention must be new” (2022) Intellectual Property Law for Engineers and Scientists, pp. 75–86. Available at: https://doi.org/10.1002/0471697400.ch6.
Abadi, H. H. N., & Pecht, M. (2020). Artificial intelligence trends based on the patents granted by the United States patent and trademark office. IEEE Access, 8, 81633-81643.
Van Norman, G. A., & Eisenkot, R. (2017). Technology transfer: from the research bench to commercialization: part 1: intellectual property rights—basics of patents and copyrights. Basic to Translational Science, 2(1), 85-97.
Van Norman, G. A., & Eisenkot, R. (2017). Technology transfer: from the research bench to commercialization: part 1: intellectual property rights—basics of patents and copyrights. Basic to Translational Science, 2(1), 56
Van Norman, G. A., & Eisenkot, R. (2017). Technology transfer: from the research bench to commercialization: part 1: intellectual property rights—basics of patents and copyrights. Basic to Translational Science, 2(1), 90-91
Van Norman, G. A., & Eisenkot, R. (2017). Technology transfer: from the research bench to commercialization: part 1: intellectual property rights—basics of patents and copyrights. Basic to Translational Science, 2(1), 94
Mueller, J. M. (2001). No Dilettante affair: Rethinking the experimental use exception to patent infringement for biomedical research tools. Wash. L. Rev., 76, 1.
The Patents Act, 1970, § 3, Acts of Parliament, 1970 21. Ecks, S. (2008). Global pharmaceutical markets and corporate citizenship: The case of Novartis’ anti-cancer drug Glivec. BioSocieties, 3(2), 165-181.
The Patent (Amendment) Act, 2005, § 3, Acts of Parliament, 2005
Raju, P. (2007). The debacle of Novartis patent case in India: Strict interpretation of patentability criteria under Article 27 of the TRIPS Agreement. The Debacle of Novartis Patent Case in India: Strict Interpretation of Patentability Criteria Under Article, 27.
Raju, P. (2007). The debacle of Novartis patent case in India: Strict interpretation of patentability criteria under Article 27 of the TRIPS Agreement. The Debacle of Novartis Patent Case in India: Strict Interpretation of Patentability Criteria Under Article, 27.
Raju, P. (2007). The debacle of Novartis patent case in India: Strict interpretation of patentability criteria under Article 27 of the TRIPS Agreement. The Debacle of Novartis Patent Case in India: Strict Interpretation of Patentability Criteria Under Article, 27.
